

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

Approved by the
Regents
December 18, 2014

ACTION REQUEST

Subject: Extension of Master Agreement between the University of Michigan and Innovative Biotherapies, Inc.

Action Requested: Authorization to extend the Master Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing a Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and agreed to by the parties involved.

This proposed extension to the Agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Dr. H. David Humes is an employee of the University of Michigan ("University"), and a founder, partial owner, director and officer of the for-profit company Innovative Biotherapies, Inc. The law permits such an Agreement provided it is disclosed to the Board of Regents ("Regents") of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Dr. H. David Humes, Professor of Internal Medicine, Division of Nephrology, is a founder, partial owner, director and officer of Innovative Biotherapies, Inc. ("the Company"). The Company was formed to commercialize therapy related to systemic inflammatory responses and other diseases and conditions technologies from the University as disclosed in a previous Regental Action Request. The Company entered into a Master Agreement with the University after receiving Regental approval on September 20, 2007. The Company wishes to continue to support research projects at the University and desires to use facilities of the University for projects related to research and development of these technologies. The role of Dr. H. David Humes will be described in a project statement for each project and shall be subject to an approved conflict of interest management plan.

Agreement Terms:

The University will continue to use standard procedures for performance of projects as well as provisions implementing University and federal policies related to intellectual property and publications. The University will amend the Agreement with the Company to extend coverage until December 31, 2017, with a total authorization increased amount not to exceed \$2,000,000. The University will use standard sponsored project accounting procedures to determine the cost of each project under this Agreement. Budgets will be reviewed and approved by authorized representatives of the applicable department(s) and school(s)/college(s) where projects will be performed. The Amendment will allow the University and the Company to continue to specify projects that the University will conduct under the

terms of the Agreement. Since sponsored projects are often amended, the Agreement includes provisions for changes in the time, amount, and scope of each supported project. University procedures for approval of each project will be followed and additional conflict of interest review will be done on a project-by-project basis.

Impact of the Agreement

The Master Agreement extension will enable the continuation of research and testing that will assist the University in developing and commercializing technology licensed to the Company for therapy related to systemic inflammatory responses and other diseases and conditions. It also provides for ongoing support and collaboration between the University and a University of Michigan start-up company.

Recommendations:

These matters will be continue to be reviewed and approved by the Medical School Conflict of Interest Board and a plan will be developed to manage the potential conflict of interest risks associated with each project that will be implemented under the terms of the Master Agreement extension prior to the University's approval of any individual project. In light of this disclosure and our finding that the Agreement extension has been negotiated in conformance with standard University practices, I recommend that the Board of Regents approve of the University extending this Agreement with Innovative Biotherapies, Inc.

Respectfully submitted,



S. Jack Hu
Interim Vice President for Research

December 2014